Trial Profile
Efficacy of duloxetine for cancer patients with neuropathic pain: Double blind, Randomized, Placebo controlled, exploratory trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Cancer pain; Neuropathic pain
- Focus Therapeutic Use
- Acronyms DIRECT
- 01 Jun 2020 Results published in the Supportive Care in Cancer
- 05 Jun 2018 Results assessing the efficacy presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2018 Status changed from active, no longer recruiting to completed.